logo

LVTX

LAVA Therapeutics
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 0
Sell signal 3
Significant Net Income Decline
EPS Below Expectations
Revenue Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000

About LVTX

Lava Therapeutics N.V.

A clinical-stage immuno-oncology company that develops new cancer treatments that leverage the immune system

Biological Technology
02/15/2016
03/25/2021
NASDAQ Stock Exchange
34
12-31
Common stock
Yalelaan 62, 3584 CM Utrecht, The Netherlands
--
LAVA Therapeutics N.V. was incorporated in the Netherlands on February 15, 2016. The company is a clinical-stage immuno-oncology company dedicated to the rapid development of new cancer treatments that harness the immune system to save patients' lives. Utilizing the company's Gammabody platform, the company is developing a series of novel bispecific antibodies designed to harness the potency and precision of γ-δ (gd) T cells to elicit a powerful natural anti-tumor immune response and improve the prognosis of cancer patients.

Company Financials

EPS

LVTX has released its 2025 Q1 earnings. EPS was reported at -0.13, versus the expected -0.414622, beating expectations. The chart below visualizes how LVTX has performed over recent quarters, highlighting trends in earnings surprises.

Forecast

Wall Street Opinions

Price Target

Volume Profile

Trade Flow Insight

Seasonals

Community Forum

Loading...

Related News

No articles available

Related Symbols

You can ask Aime